—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Liquidia Technologies Inc (LQDA) — the peer cohort

As of 2026-10-29 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Liquidia Technologies Inc ranks 7 of 7 in its cohort on the Closelooknet composite (47/100) — the cohort is led by Laboratorios Farmaceuticos ROVI at 62/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
LQDA Liquidia Technologies Inc 47 33 68 31 info 51.9%
ROVI.MC Laboratorios Farmaceuticos ROVI 62 34 77 50 info 27.8%
LNTH Lantheus Holdings Inc 60 72 74 54 ok 10.3%
BHC.TO Bausch Health Companies Inc 58 92 71 82 info 1.9%
GALDY GALDERMA GROUP AG 57 70 60 22 info 1.6%
KNSA Kiniksa Pharmaceuticals Ltd 57 97 59 18 ok 0.8%
AMRX Amneal Pharmaceuticals, Inc. Class A Common Stock 56 93 58 46 ok 1.5%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-29

Quick answers

Who are Liquidia Technologies Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Laboratorios Farmaceuticos ROVI (ROVI.MC), Lantheus Holdings Inc (LNTH), Bausch Health Companies Inc (BHC.TO), GALDERMA GROUP AG (GALDY), Kiniksa Pharmaceuticals Ltd (KNSA), Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX).

How does LQDA score against its peers?

Liquidia Technologies Inc's composite reads 47/100, ranking 7 of 7 in its cohort as of 2026-10-29; the cohort's highest composite is Laboratorios Farmaceuticos ROVI at 62/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.